Results 241 to 250 of about 444,966 (303)

Substituent‐Based Modulation of Self‐Assembly and Immunogenicity of Amphipathic Peptides

Advanced Science, EarlyView.
This study systematically investigates how positional and subtle changes, such as substituents on the phenyl ring attached to short amphipathic peptides, influence their self‐assembly, fibril morphology, and immunogenic responses. ABSTRACT Self‐assembled peptide‐based biomaterials provide versatile platforms for biomedical uses, featuring customizable ...
Anirban Das, Ushasi Pramanik, Elise M. Brown, Chih‐Yun Liu, Huan Gong, Jonathan Fascetti, Mark Gibson, Samuel Stealey, Silviya P. Zustiak, Cory Berkland, Piyoosh Sharma, Meredith E. Jackrel, Mark A. White, Jai S. Rudra   +13 more
wiley   +1 more source

Skin and Soft Tissue Mucormycosis in Patients Receiving Bruton Tyrosine Kinase Inhibitors: Case Report and Literature Review. [PDF]

Open Forum Infect Dis
Aparicio-Minguijón E, López-Muñoz N, Boán J, Pérez-Jacoiste Asín MA, de la Serna J, Pérez-Ayala A, Enguita AB, Rodríguez-Goncer I, Fernández-Ruiz M.   +8 more
europepmc   +1 more source

Chaperone‐Mediated Autophagic Degradation of USP9X in Macrophages Exacerbates Postmyocardial Infarction Inflammation and Cardiac Dysfunction

Advanced Science, EarlyView.
This study demonstrates that inflammatory stimuli induce the acetylation‐triggered, chaperone‐mediated autophagic degradation of ubiquitin‐specific peptidase 9 X‐linked (USP9X) in macrophages. USP9X acts as a macrophage “inflammation switch” after myocardial infarction (MI). USP9X loss destabilizes tumor necrosis factor receptor‐associated factor (TRAF)
Biqing Wang, Xiangheng Cai, Mengqi Li, Xue Liu, Junhui Xue, Ye Liu, Ding Ai, Xinyang Hu   +7 more
wiley   +1 more source

Considerations for the practical management of cardiovascular risk with Bruton's tyrosine kinase inhibitors for patients with chronic lymphocytic leukemia. [PDF]

Oncologist
Lenihan D, Bloom M, Copeland-Halperin R, Fleming MR, Fradley M, O'Quinn R, Bhat SA.   +6 more
europepmc   +1 more source

Targeting PRKCN, an Essential Driver Orchestrating mTOR‐IRF4 Axis Independently of Kinase Activity, in Multiple Myeloma

Advanced Science, EarlyView.
Constitutive PRKCN expression is driven by super‐enhancers and modulated by NF‐κB signaling in multiple myeloma (MM). PRKCN activates mTORC1/2‐IRF4 signaling axis and favors tumor cell growth independently of its kinase activity. IRF4 reciprocally promotes PRKCN transcription, creating a feed‐forward loop.
Koukou Tang, Dongpeng Jiang, Peng Ke, Xiaosen Bian, Lili Zhang, Ying Zhang, Tingting Zhu, Weiwei Qu, Wenhui Qi, Yang Xu, Chengcheng Fu, Depei Wu, Jianhong Chu   +12 more
wiley   +1 more source

Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNA. [PDF]

Cell Genom
Parsons HA, Messer C, Santos K, Weiss J, Merrell D, Danysh BP, Hughes ME, Kirkner GJ, Patel A, Hess J, Sendrick K, Stewart C, Grant E, Schlueter-Kuck K, Grinshpun A, Wagle N, Veeraraghavan J, Leone JP, Freedman RA, Metzger O, Schiff R, Winer EP, Tolaney SM, Rimawi M, Krop IE, Getz G, Lin NU.   +26 more
europepmc   +1 more source

254 Tyrosine kinase inhibitors

European Journal of Cancer Supplements, 2009
openaire   +1 more source

Disparate patterns of disease time burden in patients with HCC on immunotherapy or tyrosine kinase inhibitors. [PDF]

JHEP Rep
Hui RW, Chung MS, Li L, Mao X, Chiang CL, Wong CK, Wong IC, Cheung KS, Yuen MF, Seto WK, Mak LY.   +10 more
europepmc   +1 more source

Exploring research frontiers and emerging trends of tyrosine kinase inhibitors in the treatment of colorectal cancer. [PDF]

BMC Cancer
Li X, Chen Z, Yin J, Shen X, Li H.
europepmc   +1 more source